WO2000035473A3 - Methods for detection and use of differentially expressed genes in disease states - Google Patents

Methods for detection and use of differentially expressed genes in disease states Download PDF

Info

Publication number
WO2000035473A3
WO2000035473A3 PCT/US1999/029941 US9929941W WO0035473A3 WO 2000035473 A3 WO2000035473 A3 WO 2000035473A3 US 9929941 W US9929941 W US 9929941W WO 0035473 A3 WO0035473 A3 WO 0035473A3
Authority
WO
WIPO (PCT)
Prior art keywords
disease
methods
kidney
detection
differentially expressed
Prior art date
Application number
PCT/US1999/029941
Other languages
French (fr)
Other versions
WO2000035473A2 (en
Inventor
Lawrence W Stanton
R Tyler White
Deborah L Damm
John A Lewicki
Alison Joly
George F Schreiner
Original Assignee
Scios Inc
Lawrence W Stanton
R Tyler White
Deborah L Damm
John A Lewicki
Alison Joly
George F Schreiner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scios Inc, Lawrence W Stanton, R Tyler White, Deborah L Damm, John A Lewicki, Alison Joly, George F Schreiner filed Critical Scios Inc
Priority to AU20553/00A priority Critical patent/AU2055300A/en
Priority to EP99964277A priority patent/EP1140137A2/en
Publication of WO2000035473A2 publication Critical patent/WO2000035473A2/en
Publication of WO2000035473A3 publication Critical patent/WO2000035473A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to methods and compositions for the detection, diagnosis, prevention and treatment of a disease, specifically cardiac, kidney or inflammatory disease, and related disorders. The present invention also relates to compositions and methods useful in the diagnosis, prevention and therapeutic treatment of a disease, specifically cardiac, kidney or inflammatory disease. Specifically, methods and compositions are provided for the diagnostic evaluation and prognosis of conditions involving a disease, specifically cardiac, kidney or inflammatory disease, for the identification of subjects exhibiting a predisposition to such conditions, for modulating the effect of these differentially expressed genes, for monitoring patients undergoing clinical evaluation for the prevention and treatment of a disease, specifically cardiac, kidney or inflammatory disease, and its disorders, and for monitoring the efficacy of compounds used in clinical trials.
PCT/US1999/029941 1998-12-18 1999-12-15 Methods for detection and use of differentially expressed genes in disease states WO2000035473A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU20553/00A AU2055300A (en) 1998-12-18 1999-12-15 Methods for detection and use of differentially expressed genes in disease states
EP99964277A EP1140137A2 (en) 1998-12-18 1999-12-15 Method for detection and use of differentially expressed genes in disease states

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11300898P 1998-12-18 1998-12-18
US60/113,008 1998-12-18

Publications (2)

Publication Number Publication Date
WO2000035473A2 WO2000035473A2 (en) 2000-06-22
WO2000035473A3 true WO2000035473A3 (en) 2000-11-09

Family

ID=22347087

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/029941 WO2000035473A2 (en) 1998-12-18 1999-12-15 Methods for detection and use of differentially expressed genes in disease states

Country Status (3)

Country Link
EP (1) EP1140137A2 (en)
AU (1) AU2055300A (en)
WO (1) WO2000035473A2 (en)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2360282A (en) * 2000-03-17 2001-09-19 Bioinvent Int Ab Making and using micro-arrays of biological materials
WO2001073022A1 (en) * 2000-03-29 2001-10-04 Kyowa Hakko Kogyo Co., Ltd. Proliferative glomerular nephritis-associated gene
US6800455B2 (en) 2000-03-31 2004-10-05 Scios Inc. Secreted factors
US20020142284A1 (en) * 2000-07-13 2002-10-03 Debasish Raha Methods of identifying renal protective factors
IL154794A0 (en) * 2000-09-08 2003-10-31 Daiichi Suntory Pharma Co Ltd Remedies for heart failure
US7432060B2 (en) 2000-11-09 2008-10-07 The Brigham And Women's Hospital, Inc. Methods for diagnosis of cardiovascular disease
WO2002052261A1 (en) * 2000-12-22 2002-07-04 Chugai Seiyaku Kabushiki Kaisha High-throughput screening system by microarrays
IL159015A0 (en) * 2001-05-25 2004-05-12 Genset Sa Polypeptides, their preparation and use
CA2457065A1 (en) 2001-08-13 2003-02-27 Dana-Farber Cancer Institute, Inc. Periostin-based diagnostic assays
GB0120238D0 (en) * 2001-08-20 2001-10-10 Univ College Of London Sodium channel regulators and modulators
CA2460117A1 (en) * 2001-09-11 2003-03-20 The Regents Of The University Of Colorado, A Body Corporate Expression profiling in the intact human heart
US7670769B2 (en) 2002-05-09 2010-03-02 The Brigham And Women's Hospital, Inc. IL1RL-1 as a cardiovascular disease marker and therapeutic target
AU2003295598B2 (en) * 2002-11-15 2009-12-24 Genomic Health, Inc. Gene expression profiling of EGFR positive cancer
US20060275770A1 (en) * 2002-11-27 2006-12-07 Daniel Bednarik Heart failure gene determination and therapeutic screening
WO2005014022A1 (en) 2003-07-16 2005-02-17 Develogen Aktiengesellschaft Use of pleitrophin for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome
AU2004278311A1 (en) 2003-10-03 2005-04-14 Genentech, Inc. IGF binding proteins
EP1831398B1 (en) * 2004-12-08 2014-10-29 Aventis Pharmaceuticals Inc. Method for determining resistance or sensitivity to taxoid-based medicaments
WO2006085482A1 (en) * 2005-02-10 2006-08-17 Riken Self-replication factor and amplification method of hematopoietic stem cell
WO2007103541A2 (en) 2006-03-09 2007-09-13 The Trustees Of Boston University Diagnostic and prognostic methods for lung disorders using gene expression profiles from nose epithelial cells
JP5383480B2 (en) 2006-04-24 2014-01-08 クリティカル ケア ダイアグノスティクス インコーポレイテッド Predict fatality and detect serious disease
ATE545032T1 (en) 2006-05-01 2012-02-15 Critical Care Diagnostics Inc DIAGNOSIS OF CARDIOVASCULAR DISEASE
US8147817B2 (en) 2006-05-04 2012-04-03 The Brigham And Women's Hospital, Inc. IL-33 in the treatment and diagnosis of diseases and disorders
EP2498095A3 (en) * 2007-01-25 2012-11-28 Roche Diagniostics GmbH Use of IGFBP-7 in the assessment of heart failure
EP2307563B1 (en) * 2008-03-28 2014-08-06 Katholieke Universiteit Leuven KU Leuven Research & Development Mucosal gene signatures
PL2827152T3 (en) 2008-04-18 2016-12-30 Predicting risk of major adverse cardiac events
MX2011002422A (en) * 2008-09-08 2011-06-21 Ottawa Hospital Res Inst Periostin-induced pancreatic regeneration.
DK177532B1 (en) 2009-09-17 2013-09-08 Bio Bedst Aps Medical use of sPLA2 hydrolysable liposomes
WO2011084333A1 (en) * 2009-12-16 2011-07-14 Hitachi Chemical Co., Ltd. Method for characterizing host immune function by ex vivo induction of offensive and defensive immune markers
WO2011097572A1 (en) * 2010-02-05 2011-08-11 The Procter & Gamble Company Transcriptional profiling and biomarker-based methods for identifying and evaluating agents for antioxidant efficacy in cosmetic skin care formulations
US9150920B2 (en) 2010-05-07 2015-10-06 Hitachi Chemical Co., Ltd. Methods of characterizing host responsiveness to interferon by ex vivo induction of interferon-responsive markers
US20140031250A1 (en) 2010-10-07 2014-01-30 David Tsai Ting Biomarkers of Cancer
EP2686689B1 (en) 2011-03-17 2019-08-07 Critical Care Diagnostics, Inc. Methods predicting risk of an adverse clinical outcome
CN104011543B (en) * 2011-10-24 2016-06-15 通用医疗公司 The biomarker of cancer
SG11201406184XA (en) * 2012-03-30 2014-10-30 Genentech Inc Diagnostic methods and compositions for treatment of cancer
AU2013305829A1 (en) 2012-08-21 2015-03-05 Critical Care Diagnostics, Inc. Multimarker risk stratification
WO2015063244A1 (en) * 2013-10-30 2015-05-07 Servicio Andaluz De Salud Epithelial-mesenchymal transition in circulating tumor cells (ctcs) negatives for cytokeratin (ck) expression in patients with non-metastatic breast cancer
CN106661615A (en) * 2014-05-12 2017-05-10 詹森药业有限公司 Biological markers for identifying patients for treatment with abiraterone acetate
US20170248579A1 (en) * 2014-09-10 2017-08-31 The Uab Research Foundation Amyotrophic lateral sclerosis (als) biomarkers and uses thereof
EP3198035B1 (en) 2014-09-26 2022-11-02 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness
US20160122820A1 (en) * 2014-10-29 2016-05-05 Avon Products, Inc. Screening Method for Identifying Active Agents
US20160199399A1 (en) * 2015-01-09 2016-07-14 Medical Prognosis Institute A/S Methods for predicting drug responsiveness in cancer patients
US20180037956A1 (en) * 2015-03-04 2018-02-08 Hummingbird Diagnostics Gmbh Signature of health
DE112016003948T5 (en) 2015-08-31 2018-05-09 City Of Sapporo MOLECULAR METHODS FOR EVALUATING A UROTHIAL DISEASE
US9725769B1 (en) 2016-10-07 2017-08-08 Oncology Venture ApS Methods for predicting drug responsiveness in cancer patients
US10865412B2 (en) * 2016-11-04 2020-12-15 Ottawa Heart Institute Research Therapeutics targeting IGFBP7 for the treatment or prevention of heart failure and metabolic diseases
AU2017258901A1 (en) 2016-12-30 2018-07-19 Allarity Therapeutics Europe ApS Methods for predicting drug responsiveness in cancer patients
US20200110073A1 (en) * 2018-10-04 2020-04-09 The Jackson Laboratory Renal disease targets

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029448A1 (en) * 1993-06-11 1994-12-22 Nawata, Hajime Dna and protein coded for thereby
WO1996002257A1 (en) * 1994-07-18 1996-02-01 Georgetown University Antisense oligonucleotides of pleiotrophin
WO1999038973A2 (en) * 1998-01-28 1999-08-05 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994029448A1 (en) * 1993-06-11 1994-12-22 Nawata, Hajime Dna and protein coded for thereby
WO1996002257A1 (en) * 1994-07-18 1996-02-01 Georgetown University Antisense oligonucleotides of pleiotrophin
WO1999038973A2 (en) * 1998-01-28 1999-08-05 Corixa Corporation Compounds for therapy and diagnosis of lung cancer and methods for their use

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
DATABASE EMBL 1995, MIZUSHIMA S ET AL: "DNA ENCODING A PROTEIN PROMOTING PG12 PRODUCTION", XP002136679 *
DATABASE EMBL 1996, COLLEY KJ ET AL: "Antisense oligonucleotides of pleiotrophin", XP002136678 *
DATABASE EMBL 26 May 1993 (1993-05-26), LEWIN A.R. ET AL: "Molecular analysis of a human interferon-inducible gene family", XP002136677 *
EUR. J. BIOCHEM. 199:417-423, 1991 *
HELLER R.A. ET AL: "Discovery and analysis of inflammatory disease-related genes using cDNA microarrays", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 94, 1997, pages 2150 - 2155, XP002136673 *
IMAI S ET AL: "Osteoblast recruitment and bone formation enhanced by cell matrix-associated heparin-binding growth-associated molecule (HB-GAM)", THE JOURNAL OF CELL BIOLOGY,US,ROCKEFELLER UNIVERSITY PRESS, vol. 143, no. 4, 16 November 1998 (1998-11-16), pages 1113 - 1128-1128, XP002102012, ISSN: 0021-9525 *
MAEDA K. ET AL: "Analysis of an expression profile of genes in the human adipose tissue", GENE, vol. 190, 1997, pages 227 - 235, XP002136672 *
MASUDA H ET AL: "Bone loss due to estrogen deficieny is compensated in transgenic mice overexpressing human osteoblast stimulating factor-1", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS,US,ACADEMIC PRESS INC. ORLANDO, FL, vol. 238, no. 238, 1997, pages 528 - 533-533, XP002100860, ISSN: 0006-291X *
SCHENA M. ET AL: "parallel human genome analysis: Microarray-based expression monitoring of 1000 genes", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES USA, vol. 93, 1996, pages 10614 - 10619, XP002136674 *

Also Published As

Publication number Publication date
AU2055300A (en) 2000-07-03
WO2000035473A2 (en) 2000-06-22
EP1140137A2 (en) 2001-10-10

Similar Documents

Publication Publication Date Title
WO2000035473A3 (en) Methods for detection and use of differentially expressed genes in disease states
EP0904277A4 (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
EP1403372A3 (en) Composition and methods for the treatment and diagnosis of cardiovascular disease
WO2004065576A3 (en) Methods and compositions for the treatment of urological disorder using differential expressed polypeptides
WO2001089564A3 (en) Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
Bidlingmeyer et al. Isolated office hypertension: a prehypertensive state?
EP1100547A4 (en) Compositions and methods for the treatment and diagnosis of cardiovascular disease
CA2421007A1 (en) Method for detection of htr and htert telomerase-associated rna in plasma or serum
WO2005020784A3 (en) Surrogate cell gene expression signatures for evaluating the physical state of a subject
NO20002380D0 (en) Compounds for pre-death diagnosis of Alzheimer's disease and in vivo imaging, as well as prevention of amyloid deposition
DE50103907D1 (en) Uses of aldose-1-epimerase (mutarotase) for the diagnosis of inflammatory diseases and sepsis
WO2003065984A3 (en) Methods and compositions for treating cardiovascular disease
WO2001081634A3 (en) Methods and compositions for the diagnosis and treatment of cardiovascular and tumorigenic disease using 4941
WO2004063340A3 (en) Methods and compositions for treating cardiovascular disease using 1722, 10280, 59917, 85553, 10653, 9235, 21668, 17794, 2210, 6169, 10102, 21061,17662,1468,12282, 6350, 9035,1820, 23652, 7301, 8925, 8701, 3533, 9462, 9123,12788,17729, 65552,1261, 21476, 33770, 9380, 2569654, 33556, 53656, 44143, 32612, 10671, 261, 44570, 4
WO2003070883A3 (en) Methods and compositions for treating aids and hiv-related disorders using 1414, 1481, 1553, 34021, 1720, 1683, 1552, 1682, 1675, 12825, 9952, 5816, 10002, 1611, 1371, 14324, 126, 270, 312, 167, 326, 18926, 6747, 1793, 1784, or 2045 molecules.
WO2004072242A3 (en) Screening of compounds for hematological disorder treatment
WO2002016636A3 (en) Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders
WO2003065871A3 (en) Methods and compositions for treating hematological disorders
WO2003073983A3 (en) Methods and compositions in treating pain using diacylglycerol kinase epsilon
WO2004018710A3 (en) Diagnosis of chronic rejection
WO2003050504A3 (en) Methods and compositions to treat cardiovascular disease usin g 1419, 58765 and 2201
Stewart et al. An acute attack of variegate porphyria complicated by severe autonomic neuropathy
WO2004001422A3 (en) Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases
WO2001088157A3 (en) Treatment methods using 17906 and uses therefor
WO2003061573A3 (en) Methods and compositions for treating urological disorders using 1435, 559, 34021, 44099, 25278, 641, 260, 55089, 21407, 42032, 46656, 62553, 302, 323, 12303, 985, 13237, 13601, 18926, 318, 2058 or 6351 mo

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ CZ DE DE DK DK DM EE EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999964277

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999964277

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWR Wipo information: refused in national office

Ref document number: 1999964277

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1999964277

Country of ref document: EP